A detailed history of Creative Planning transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Creative Planning holds 46,834 shares of HALO stock, worth $2.21 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
46,834
Previous 37,291 25.59%
Holding current value
$2.21 Million
Previous $1.95 Million 37.24%
% of portfolio
0.0%
Previous 0.0%

Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 11, 2024

BUY
$51.3 - $64.42 $489,555 - $614,760
9,543 Added 25.59%
46,834 $2.68 Million
Q2 2024

Aug 15, 2024

BUY
$37.81 - $52.4 $425,324 - $589,447
11,249 Added 43.2%
37,291 $1.95 Million
Q1 2024

May 10, 2024

BUY
$33.68 - $41.95 $151,829 - $189,110
4,508 Added 20.93%
26,042 $1.06 Million
Q4 2023

Feb 14, 2024

BUY
$33.32 - $42.1 $158,369 - $200,101
4,753 Added 28.32%
21,534 $795,000
Q3 2023

Nov 16, 2023

BUY
$36.46 - $44.03 $120,719 - $145,783
3,311 Added 24.58%
16,781 $641,000
Q2 2023

Jul 21, 2023

BUY
$30.28 - $38.74 $407,871 - $521,827
13,470 New
13,470 $485,000
Q4 2022

Feb 10, 2023

BUY
$40.06 - $59.44 $193,249 - $286,738
4,824 New
4,824 $274,000
Q1 2020

May 05, 2020

SELL
$13.9 - $21.83 $148,618 - $233,406
-10,692 Closed
0 $0
Q4 2019

Jan 30, 2020

SELL
$14.93 - $19.53 $343,390 - $449,190
-23,000 Reduced 68.27%
10,692 $190,000
Q2 2019

Jul 26, 2019

SELL
$14.75 - $17.26 $73,750 - $86,300
-5,000 Reduced 12.92%
33,692 $579,000
Q1 2019

Apr 24, 2019

SELL
$13.94 - $17.58 $341,530 - $430,709
-24,500 Reduced 38.77%
38,692 $623,000
Q4 2018

Feb 01, 2019

SELL
$13.33 - $18.66 $7,998 - $11,196
-600 Reduced 0.94%
63,192 $924,000
Q3 2018

Oct 25, 2018

SELL
$16.68 - $18.41 $166,800 - $184,100
-10,000 Reduced 13.55%
63,792 $1.16 Million
Q2 2018

Jul 20, 2018

SELL
$16.87 - $20.3 $185,570 - $223,300
-11,000 Reduced 12.97%
73,792 $1.25 Million
Q1 2018

Apr 18, 2018

SELL
$17.06 - $21.2 $49,303 - $61,268
-2,890 Reduced 3.3%
84,792 $1.66 Million
Q4 2017

Jan 17, 2018

SELL
$16.75 - $20.8 $23,617 - $29,328
-1,410 Reduced 1.58%
87,682 $1.78 Million
Q3 2017

Oct 17, 2017

BUY
$11.76 - $17.4 $1.05 Million - $1.55 Million
89,092
89,092 $1.55 Million

Others Institutions Holding HALO

About HALOZYME THERAPEUTICS, INC.


  • Ticker HALO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 139,288,992
  • Market Cap $6.57B
  • Description
  • Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...
More about HALO
Track This Portfolio

Track Creative Planning Portfolio

Follow Creative Planning and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Creative Planning, based on Form 13F filings with the SEC.

News

Stay updated on Creative Planning with notifications on news.